drugset / Trial / NCT00034918

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

NCT00034918

Phase 2 Completed 44 enrolled Genzyme, a Sanofi Company
Non-randomizedFactorialOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy of ZD6474 in patients with metastatic breast cancer at 2 dose levels.

Timeline

Start
2002-05
Primary completion
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule 100 mg Oral
Subject Vandetanib Small molecule 300 mg Oral